TY - JOUR AU - Hasanabady, M. H. AU - Kalalinia, F. PY - 2016 DA - 2016// TI - ABCG2 inhibition as a therapeutic approach for overcoming multidrug resistance in cancer JO - J Biosci VL - 41 UR - https://doi.org/10.1007/s12038-016-9601-5 DO - 10.1007/s12038-016-9601-5 ID - Hasanabady2016 ER - TY - JOUR AU - Gottesman, M. M. PY - 2002 DA - 2002// TI - Mechanisms of cancer drug resistance JO - Annu Rev Med VL - 53 UR - https://doi.org/10.1146/annurev.med.53.082901.103929 DO - 10.1146/annurev.med.53.082901.103929 ID - Gottesman2002 ER - TY - JOUR AU - Choudhuri, S. AU - Klaassen, C. D. PY - 2006 DA - 2006// TI - Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters JO - Int J Toxicol VL - 25 UR - https://doi.org/10.1080/10915810600746023 DO - 10.1080/10915810600746023 ID - Choudhuri2006 ER - TY - JOUR AU - Gatti, L. AU - Beretta, G. L. AU - Cossa, G. AU - Zunino, F. AU - Perego, P. PY - 2009 DA - 2009// TI - ABC transporters as potential targets for modulation of drug resistance JO - Mini-Rev Med Chem VL - 9 UR - https://doi.org/10.2174/138955709788922656 DO - 10.2174/138955709788922656 ID - Gatti2009 ER - TY - JOUR AU - Doyle, L. A. AU - Yang, W. AU - Abruzzo, L. V. AU - Krogmann, T. AU - Gao, Y. AU - Rishi, A. K. PY - 1998 DA - 1998// TI - A multidrug resistance transporter from human MCF-7 breast cancer cells JO - Proc Natl Acad Sci U S A VL - 95 UR - https://doi.org/10.1073/pnas.95.26.15665 DO - 10.1073/pnas.95.26.15665 ID - Doyle1998 ER - TY - JOUR AU - Jain, H. D. AU - Zhang, C. AU - Zhou, S. AU - Zhou, H. AU - Ma, J. AU - Liu, X. PY - 2008 DA - 2008// TI - Synthesis and structure-activity relationship studies on tryprostatin A, an inhibitor of breast cancer resistance protein JO - Bioorg Med Chem VL - 16 UR - https://doi.org/10.1016/j.bmc.2008.02.050 DO - 10.1016/j.bmc.2008.02.050 ID - Jain2008 ER - TY - JOUR AU - Borst, P. AU - Elferink, R. O. PY - 2002 DA - 2002// TI - Mammalian ABC transporters in health and disease JO - Annu Rev Biochem VL - 71 UR - https://doi.org/10.1146/annurev.biochem.71.102301.093055 DO - 10.1146/annurev.biochem.71.102301.093055 ID - Borst2002 ER - TY - JOUR AU - Han, J. Y. AU - Lim, H. S. AU - Yoo, Y. K. AU - Shin, E. S. AU - Park, Y. H. AU - Lee, S. Y. PY - 2007 DA - 2007// TI - Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer JO - Cancer VL - 110 UR - https://doi.org/10.1002/cncr.22760 DO - 10.1002/cncr.22760 ID - Han2007 ER - TY - JOUR AU - Zhou, Y. AU - Sridhar, R. AU - Shan, L. AU - Sha, W. AU - Gu, X. AU - Sukumar, S. PY - 2012 DA - 2012// TI - Loperamide, an FDA-approved antidiarrhea drug, effectively reverses the resistance of multidrug resistant MCF-7/MDR1 human breast cancer cells to doxorubicin-induced cytotoxicity JO - Cancer Investig VL - 30 UR - https://doi.org/10.3109/07357907.2011.640653 DO - 10.3109/07357907.2011.640653 ID - Zhou2012 ER - TY - JOUR AU - Li, J. AU - Xu, L. Z. AU - He, K. L. AU - Guo, W. J. AU - Zheng, Y. H. AU - Xia, P. PY - 2001 DA - 2001// TI - Reversal effects of nomegestrol acetate on multidrug resistance in adriamycin-resistant MCF7 breast cancer cell line JO - Breast Cancer Res VL - 3 UR - https://doi.org/10.1186/bcr303 DO - 10.1186/bcr303 ID - Li2001 ER - TY - JOUR AU - Szakacs, G. AU - Paterson, J. K. AU - Ludwig, J. A. AU - Booth-Genthe, C. AU - Gottesman, M. M. PY - 2006 DA - 2006// TI - Targeting multidrug resistance in cancer. Nature reviews JO - Drug Des Discov VL - 5 UR - https://doi.org/10.1038/nrd1984 DO - 10.1038/nrd1984 ID - Szakacs2006 ER - TY - JOUR AU - Dai, C. L. AU - Tiwari, A. K. AU - Wu, C. P. AU - Su, X. D. AU - Wang, S. R. AU - Liu, D. G. PY - 2008 DA - 2008// TI - Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2 JO - Cancer Res VL - 68 UR - https://doi.org/10.1158/0008-5472.CAN-08-0499 DO - 10.1158/0008-5472.CAN-08-0499 ID - Dai2008 ER - TY - JOUR AU - Yang, K. AU - Chen, Y. AU - Wang, F. AU - Li, D. AU - Chen, L. PY - 2017 DA - 2017// TI - Alectinib (CH5424802) antagonizes ABCB1- and ABCG2-mediated multidrug resistance in vitro, in vivo and ex vivo JO - Exp Mol Med VL - 49 UR - https://doi.org/10.1038/emm.2016.168 DO - 10.1038/emm.2016.168 ID - Yang2017 ER - TY - JOUR AU - Tong, X. AU - Wang, F. AU - Liang, S. AU - Zhang, X. AU - He, J. AU - Chen, X. PY - 2012 DA - 2012// TI - Apatinib (YN968D1) enhances the efficacy of conventional chemotherapeutical drugs in side population cells and ABCB1-overexpressing leukemia cells JO - Biochem Pharmacol VL - 83 UR - https://doi.org/10.1016/j.bcp.2011.12.007 DO - 10.1016/j.bcp.2011.12.007 ID - Tong2012 ER - TY - JOUR AU - Wu, Y. AU - Cheng, Y. AU - Zhou, X. AU - Lee, K. H. AU - Nakagawa, K. AU - Niho, S. PY - 2017 DA - 2017// TI - Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial JO - Lancet Oncol VL - 18 UR - https://doi.org/10.1016/S1470-2045(17)30608-3 DO - 10.1016/S1470-2045(17)30608-3 ID - Wu2017 ER - TY - JOUR AU - Momeny, M. AU - Zarrinrad, G. AU - Moghaddaskho, F. AU - Poursheikhani, A. AU - Sankanian, G. AU - Zaghal, A. PY - 2017 DA - 2017// TI - Dacomitinib, a pan-inhibitor of ErbB receptors, suppresses growth and invasive capacity of chemoresistant ovarian carcinoma cells JO - Sci Rep VL - 7 UR - https://doi.org/10.1038/s41598-017-04147-0 DO - 10.1038/s41598-017-04147-0 ID - Momeny2017 ER - TY - STD TI - Abdul Razak AR, Soulières D, Laurie SA, Hotte SJ, Singh S, Winquist E, et al. A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck. Annals of Oncology Official Journal of the European Society for Medical Oncology. 2013;24:761. ID - ref17 ER - TY - JOUR AU - Yu, H. A. AU - Ahn, M. AU - Cho, B. C. AU - Gerber, D. E. AU - Natale, R. B. AU - Socinski, M. A. PY - 2017 DA - 2017// TI - Phase 2 study of intermittent pulse dacomitinib in patients with advanced non-small cell lung cancers JO - Lung Cancer VL - 112 UR - https://doi.org/10.1016/j.lungcan.2017.08.017 DO - 10.1016/j.lungcan.2017.08.017 ID - Yu2017 ER - TY - JOUR AU - Calvo, E. AU - Soria, J. C. AU - Ma, W. W. AU - Wang, T. AU - Bahleda, R. AU - Tolcher, A. W. PY - 2017 DA - 2017// TI - A Phase I Clinical Trial and Independent Patient-Derived Xenograft Study of Combined Targeted Treatment with Dacomitinib and Figitumumab in Advanced Solid Tumors JO - Clin Cancer Res VL - 23 UR - https://doi.org/10.1158/1078-0432.CCR-15-2301 DO - 10.1158/1078-0432.CCR-15-2301 ID - Calvo2017 ER - TY - JOUR AU - Henrich, C. AU - Bokesch, H. AU - Dean, M. S. AU - Robey, R. AU - Goncharova, E. AU - Wilson, J. PY - 2006 DA - 2006// TI - A high-throughput cell-based assay for inhibitors of ABCG2 activity JO - J Biomol Screen VL - 11 UR - https://doi.org/10.1177/1087057105284576 DO - 10.1177/1087057105284576 ID - Henrich2006 ER - TY - JOUR AU - Zhang, J. Y. AU - Wu, H. Y. AU - Xia, X. K. AU - Liang, Y. J. AU - Yan, Y. Y. AU - She, Z. G. PY - 2007 DA - 2007// TI - Anthracenedione derivative 1403P-3 induces apoptosis in KB and KBv200 cells via reactive oxygen species-independent mitochondrial pathway and death receptor pathway JO - Cancer Biol Ther VL - 6 ID - Zhang2007 ER - TY - JOUR AU - Robey, R. W. AU - Honjo, Y. AU - Morisaki, K. AU - Nadjem, T. A. AU - Runge, S. AU - Risbood, M. PY - 2003 DA - 2003// TI - Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity JO - Br J Cancer VL - 89 UR - https://doi.org/10.1038/sj.bjc.6601370 DO - 10.1038/sj.bjc.6601370 ID - Robey2003 ER - TY - JOUR AU - Robey, R. W. AU - Shukla, S. AU - Finley, E. M. AU - Oldham, R. K. AU - Barnett, D. AU - Ambudkar, S. V. PY - 2008 DA - 2008// TI - Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)) JO - Biochem Pharmacol VL - 75 UR - https://doi.org/10.1016/j.bcp.2007.12.001 DO - 10.1016/j.bcp.2007.12.001 ID - Robey2008 ER - TY - JOUR AU - Robey, R. W. AU - Honjo, Y. AU - Morisaki, K. AU - Nadjem, T. A. AU - Runge, S. AU - Risbood, M. PY - 2003 DA - 2003// TI - Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity JO - Br J Cancer VL - 89 UR - https://doi.org/10.1038/sj.bjc.6601370 DO - 10.1038/sj.bjc.6601370 ID - Robey2003 ER - TY - JOUR AU - Gerlier, D. AU - Thomasset, N. PY - 1986 DA - 1986// TI - Use of MTT colorimetric assay to measure cell activation JO - J Immunol Methods VL - 94 UR - https://doi.org/10.1016/0022-1759(86)90215-2 DO - 10.1016/0022-1759(86)90215-2 ID - Gerlier1986 ER - TY - JOUR AU - Rabindran, S. K. AU - Ross, D. D. AU - Doyle, L. A. AU - Yang, W. AU - Greenberger, L. M. PY - 2000 DA - 2000// TI - Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein JO - Cancer Res VL - 60 ID - Rabindran2000 ER - TY - JOUR AU - Zhang, W. AU - Chen, Z. AU - Chen, L. AU - Wang, F. AU - Li, F. AU - Wang, X. PY - 2017 DA - 2017// TI - ABCG2-overexpressing H460/MX20 cell xenografts in athymic nude mice maintained original biochemical and cytological characteristics JO - Sci Rep VL - 7 UR - https://doi.org/10.1038/srep40064 DO - 10.1038/srep40064 ID - Zhang2017 ER - TY - JOUR AU - Dai, C. L. AU - Liang, Y. J. AU - Wang, Y. S. AU - Tiwari, A. K. AU - Yan, Y. Y. AU - Wang, F. PY - 2009 DA - 2009// TI - Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2 JO - Cancer Lett VL - 279 UR - https://doi.org/10.1016/j.canlet.2009.01.027 DO - 10.1016/j.canlet.2009.01.027 ID - Dai2009 ER - TY - JOUR AU - Mao, Q. PY - 2005 DA - 2005// TI - Role of the breast cancer resistance protein (ABCG2) in drug transport JO - AAPS J VL - 7 UR - https://doi.org/10.1208/aapsj070112 DO - 10.1208/aapsj070112 ID - Mao2005 ER - TY - JOUR AU - Hrycyna, C. A. AU - Ramachandra, M. AU - Ambudkar, S. V. AU - Ko, Y. H. AU - Pedersen, P. L. AU - Pastan, I. PY - 1998 DA - 1998// TI - Mechanism of action of human P-glycoprotein ATPase activity. Photochemical cleavage during a catalytic transition state using orthovanadate reveals cross-talk between the two ATP sites JO - J Biol Chem VL - 273 UR - https://doi.org/10.1074/jbc.273.27.16631 DO - 10.1074/jbc.273.27.16631 ID - Hrycyna1998 ER - TY - JOUR AU - Zhou, W. AU - Zhang, X. AU - Cheng, C. AU - Wang, F. AU - Wang, X. AU - Liang, Y. PY - 2012 DA - 2012// TI - Crizotinib (PF-02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P-glycoprotein JO - Br J Pharmacol VL - 166 UR - https://doi.org/10.1111/j.1476-5381.2012.01849.x DO - 10.1111/j.1476-5381.2012.01849.x ID - Zhou2012 ER - TY - JOUR AU - Shukla, S. AU - Robey, R. W. AU - Bates, S. E. AU - Ambudkar, S. V. PY - 2006 DA - 2006// TI - The calcium channel blockers, 1,4-dihydropyridines, are substrates of the multidrug resistance-linked ABC drug transporter, ABCG2 JO - Biochemistry VL - 45 UR - https://doi.org/10.1021/bi060552f DO - 10.1021/bi060552f ID - Shukla2006 ER - TY - JOUR AU - Livak, K. J. AU - Schmittgen, T. D. PY - 2012 DA - 2012// TI - Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method JO - Methods VL - 25 UR - https://doi.org/10.1006/meth.2001.1262 DO - 10.1006/meth.2001.1262 ID - Livak2012 ER - TY - JOUR AU - Sarkadi, B. AU - Homolya, L. AU - Szakacs, G. AU - Varadi, A. PY - 2006 DA - 2006// TI - Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system JO - Physiol Rev VL - 86 UR - https://doi.org/10.1152/physrev.00037.2005 DO - 10.1152/physrev.00037.2005 ID - Sarkadi2006 ER - TY - STD TI - Boyer MJ, Janne PA, Mok T, O'Byrne KJ, Pazares LG, Ramalingam SS, et al. ARCHER: Dacomitinib (D; PF-00299804) versus erlotinib (E) for advanced (adv) non-small cell lung cancer (NSCLC)—A randomized double-blind phase III study. J Clin Oncol. 2012;30(suppl; abstr TPS7615). ID - ref35 ER - TY - JOUR AU - Boyer, M. AU - Jänne, P. A. AU - Mok, T. AU - O'Byrne, K. AU - Paz-Ares, L. AU - Ramalingam, S. S. PY - 2013 DA - 2013// TI - Rationale and study design of ARCHER: a randomized, double-blind, Phase III study of dacomitinib versus erlotinib for advanced non-small-cell lung cancer JO - Clin Inv VL - 3 ID - Boyer2013 ER - TY - JOUR AU - Ramalingam, S. S. AU - Blackhall, F. AU - Krzakowski, M. AU - Barrios, C. H. AU - Park, K. AU - Bover, I. PY - 2012 DA - 2012// TI - Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan–Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer JO - J Clin Oncol VL - 30 UR - https://doi.org/10.1200/JCO.2011.40.9433 DO - 10.1200/JCO.2011.40.9433 ID - Ramalingam2012 ER -